GRI BIO, Inc. Files 8-K/A Amendment on Listing Status
Ticker: GRI · Form: 8-K/A · Filed: Sep 11, 2024 · CIK: 1824293
| Field | Detail |
|---|---|
| Company | Gri Bio, INC. (GRI) |
| Form Type | 8-K/A |
| Filed Date | Sep 11, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $1.00, $0.10 |
| Sentiment | neutral |
Sentiment: neutral
Topics: delisting, listing-standards, amendment
TL;DR
GRI BIO's listing is shaky, they filed an amendment on 9/10.
AI Summary
GRI BIO, Inc. filed an amendment (8-K/A) on September 11, 2024, regarding a notice of delisting or failure to satisfy continued listing rules. This filing relates to events occurring on September 10, 2024, and concerns the company's listing status.
Why It Matters
This filing indicates potential issues with GRI BIO, Inc.'s continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: medium — Filings related to delisting or failure to meet listing standards suggest potential financial or operational distress, increasing risk for investors.
Key Players & Entities
- GRI BIO, Inc. (company) — Registrant
- Vallon Pharmaceuticals, Inc. (company) — Former company name
- September 10, 2024 (date) — Earliest event date
- September 11, 2024 (date) — Filing date
FAQ
What is the primary reason for GRI BIO, Inc.'s 8-K/A filing?
The 8-K/A filing is an amendment related to a notice of delisting or failure to satisfy a continued listing rule or standard.
What was the date of the earliest event reported in this filing?
The earliest event reported was on September 10, 2024.
When was this 8-K/A amendment filed with the SEC?
The amendment was filed on September 11, 2024.
What was GRI BIO, Inc.'s former company name?
GRI BIO, Inc.'s former company name was Vallon Pharmaceuticals, Inc.
What is the principal executive office address for GRI BIO, Inc.?
The principal executive office is located at 2223 Avenida de la Playa, Suite 208, La Jolla, CA 92037.
Filing Stats: 735 words · 3 min read · ~2 pages · Grade level 12 · Accepted 2024-09-11 16:36:50
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share GRI The Nasdaq Capital Mark
- $1.00 — he Company's common stock was less than $1.00 for the previous 30 consecutive busines
- $0.10 — common stock has a closing bid price of $0.10 per share or less for ten consecutive t
Filing Documents
- val-20240910.htm (8-K/A) — 22KB
- val-20240910_g1.jpg (GRAPHIC) — 16KB
- val-20240910_g2.jpg (GRAPHIC) — 2KB
- 0001824293-24-000138.txt ( ) — 187KB
- val-20240910.xsd (EX-101.SCH) — 2KB
- val-20240910_def.xml (EX-101.DEF) — 3KB
- val-20240910_lab.xml (EX-101.LAB) — 24KB
- val-20240910_pre.xml (EX-101.PRE) — 15KB
- val-20240910_htm.xml (XML) — 3KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 10, 2024, GRI Bio, Inc. (the "Company") received a letter (the "Letter") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market, LLC ("Nasdaq"), indicating that the Company no longer meets the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement") because the closing bid price for the Company's common stock was less than $1.00 for the previous 30 consecutive business days. The Letter does not have an immediate effect on the Company's continued listing on The Nasdaq Capital Market. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a 180-calendar day period, or until March 10, 2025 (the "Compliance Date"), to regain compliance with the Minimum Bid Price Requirement. The Minimum Bid Price Requirement will be met if the Company's common stock has a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180-calendar day period, unless Nasdaq exercises its discretion to extend such 10day period. If the Company does not regain compliance by the Compliance Date, the Company may be eligible for an additional 180-calendar day period, subject to satisfying the conditions in the applicable Nasdaq Listing Rules. If, before the Compliance Date, the Company's common stock has a closing bid price of $0.10 per share or less for ten consecutive trading days, the Staff will issue a Staff Delisting Determination under Nasdaq Listing Rule 5810 with respect to the Company's common stock. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement. The Company is monitoring the closing bid price of its common stock and will consider options to regain compliance with the Minimum Bid Price Requirement.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 11, 2024 GRI Bio, Inc. By: /s/ Leanne Kelly Leanne Kelly Chief Financial Officer